JP2012507268A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507268A5
JP2012507268A5 JP2011533565A JP2011533565A JP2012507268A5 JP 2012507268 A5 JP2012507268 A5 JP 2012507268A5 JP 2011533565 A JP2011533565 A JP 2011533565A JP 2011533565 A JP2011533565 A JP 2011533565A JP 2012507268 A5 JP2012507268 A5 JP 2012507268A5
Authority
JP
Japan
Prior art keywords
meteef1a
metap2
concentration
activity
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507268A (ja
JP5347028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/007102 external-priority patent/WO2010051882A1/en
Publication of JP2012507268A publication Critical patent/JP2012507268A/ja
Publication of JP2012507268A5 publication Critical patent/JP2012507268A5/ja
Application granted granted Critical
Publication of JP5347028B2 publication Critical patent/JP5347028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533565A 2008-11-06 2009-10-05 バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法 Active JP5347028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08019432.7 2008-11-06
EP08019432 2008-11-06
PCT/EP2009/007102 WO2010051882A1 (en) 2008-11-06 2009-10-05 Use of eef1a as biomarker and a method of screening metap2 inhibitors

Publications (3)

Publication Number Publication Date
JP2012507268A JP2012507268A (ja) 2012-03-29
JP2012507268A5 true JP2012507268A5 (https=) 2012-11-22
JP5347028B2 JP5347028B2 (ja) 2013-11-20

Family

ID=41409225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533565A Active JP5347028B2 (ja) 2008-11-06 2009-10-05 バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法

Country Status (8)

Country Link
US (1) US9151743B2 (https=)
EP (1) EP2344665B1 (https=)
JP (1) JP5347028B2 (https=)
AU (1) AU2009313167C1 (https=)
CA (1) CA2742737C (https=)
ES (1) ES2402564T3 (https=)
IL (1) IL212664A0 (https=)
WO (1) WO2010051882A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
KR101712982B1 (ko) * 2015-07-31 2017-03-07 고려대학교 산학협력단 비알콜성지방간 조절인자 14-3-3 단백질
WO2018148638A1 (en) * 2017-02-10 2018-08-16 Zafgen, Inc. Pharmaceutical compositions of metap-2 inhibitors
CN108611352B (zh) * 2018-04-20 2020-08-07 华南农业大学 一种拟禾本科根结线虫翻译延长因子Mg-eEF1A及其防治植物病害的应用
EP4100007A4 (en) * 2020-02-06 2024-05-29 The Regents of the University of California STRETCH FACTOR-1 ALPHA INHIBITORS AND THEIR USES
CN116395718B (zh) * 2023-04-12 2024-12-17 中国科学院长春应用化学研究所 一种弱碱性钠盐纳米药物、其制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
JP2004514122A (ja) * 2000-11-14 2004-05-13 ノバルティス　アクチエンゲゼルシャフト 抗増殖性化合物をスクリーニングしかつ腫瘍増殖を阻害する方法
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030232383A1 (en) 2001-11-02 2003-12-18 Sylvia Daunert Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein

Similar Documents

Publication Publication Date Title
US10329354B2 (en) Modulation of efferocytosis pathways for treatment of atherosclerotic disease
Shere et al. Circulating blood biomarkers in essential hypertension: a literature review
CN104569436B (zh) Adamts1作为主动脉夹层临床筛查分子标记物的应用
KR102266302B1 (ko) 심혈관 질환 또는 문제 위험 예측용 방법 및 키트
JP2012507268A5 (https=)
Zhang et al. Sex-specific differences in the modulation of Growth Differentiation Factor 15 (GDF15) by hyperoxia in vivo and in vitro: Role of Hif-1α
Xu et al. PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice
RU2609649C2 (ru) Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке
CN114752669A (zh) 一种环状rna在制备脑卒中诊断产品中的应用
ES2665849T3 (es) Biomarcador para el diagnóstico de envejecimiento o amiotrofia
Tanios et al. CXCR4: a potential marker for inflammatory activity in abdominal aortic aneurysm wall
Ablooglu et al. Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease
Wang et al. CC chemokine receptor 5 signaling contributes to cardiac remodeling and dysfunction under pressure overload
Amer et al. Rosuvastatin restores liver tissue-resident NK cell activation in aged mice by improving mitochondrial function
JP2019200077A (ja) 肝細胞癌の診断マーカー
JP2011519030A (ja) ヒトおよび動物における生物学的老化、再生能、発癌リスク、加齢性疾患を発症するリスクおよび慢性疾患の予後を測定するための、ｄｎａ損傷およびテロメア機能不全を測定するためのマーカー
TWI359271B (en) Pharmaceutical composition for insulin resistance
Xu et al. Serum CIAPIN1 is lower in septic patients with cardiac dysfunction
US20230192882A1 (en) Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis
Slevin et al. Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis
van der Velde et al. Cardiovascular biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development
Wang et al. PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)
Gao et al. Cross-Species Multi-Omics Profiling Identifies Conserved Activated Valvular Interstitial Cell Population Driving Myxomatous Mitral Valve Degeneration
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
JP2012127879A (ja) 腎症の進行度の判定方法並びに線維化抑制剤。